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Abstract: The perceived health and environmental risks of genetically modified (GM) 
technology have impeded its diffusion in developed countries.  However, GM crops, which can 
provide direct consumer as well as producer value, have recently been developed.  This study 
applies a stated choice experiment to examine whether the addition of a medical benefit can 
improve the welfare of the beneficiaries of the newly developed GM variety.  Our results show 
a tradeoff between general worries over GM technology and GM food’s specific health benefits.  
A marketing program should therefore be designed to inform and persuade consumers of these 
features. 
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Demand for a Transgenic Food with a Medical Benefit 
1. Introduction 
Most genetically modified (GM) crop varieties developed thus far have been designed to reduce 
farm costs, through herbicide tolerance and insect resistance, for example.  Because these cost 
features have a direct appeal only to producers, consumers in developed countries—especially 
those in the European Union and Japan—generally see no particular advantage in consuming 
these products other than their arguably lower prices.  Instead, they are concerned about these 
products, particularly their perceived risks to health and the environment (Costa-Font et al., 
2008).  As a result, mitigating their concerns has been considered crucial for the diffusion of 
GM technology.  The risk-communication literature, for instance, has extensively analyzed 
consumers’ risk perception to improve their understanding of GM technology (Savadori et al., 
2004; Frewer et al., 1998).  However, given the ever-growing concerns about GM technology, 
some studies (e.g., Gaskell et al., 2004) conclude that the diffusion of GM food is slow not 
because of consumers’ misperceptions of its risks but because of the lack of perceived benefits 
from GM food consumption.   
Recent developments in GM technology enable breeders to develop new varieties that 
can provide direct consumer and producer value (Sabalza et al., 2014).  Golden rice, for 
instance, can provide vitamin A to expectant mothers, supply micronutrients to undernourished 
children, and help alleviate hidden hunger in developing economies (Hefferon, 2015).  Recent 
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studies (Lusk et al., 2002; Lusk, 2003; Corrigan et al., 2009; De Steur et al., 2010; Deodhar et 
al., 2008) examine consumers’ attitudes to GM products with direct consumer benefits, such as 
a nutritional functionality and increased shelf life.  Among health-related benefits, Gaskell 
(2000) concludes that the medical application of GM technology attracts most consumers’ 
attention (see also Fischhoff and Fischhoff, 2001).  Similarly, Einsiedel and Medlock (2005) 
find that edible vaccines from GM crops represent the most widely accepted use of the 
technology.  Consequently, second-generation GM products, which have direct appeal to 
consumers, are expected to overcome consumers’ concerns about the health and environmental 
risks of GM crops (Burton and Pearse, 2002). 
Consumers can generally be classified into two groups: infected patients and non-
infected consumers.  The former considers both the medical benefits and the risks of GM 
technology when choosing between conventional and GM foods, while the latter generally do not 
seek medical benefits, as they do not suffer from diseases.  A weakness of the aforementioned 
studies is that they attempt to measure consumers’ preference for hypothetical GM products (e.g., 
hypothetical foods that can reduce cholesterol levels) and include both the beneficiaries and non-
beneficiaries of the products as respondents in their consumer surveys.  Consequently, the 
estimated preference for hypothetical GM crops might be underestimated due to the non-
beneficiaries’ weak preference for GM products with a medical functionality.   
This study evaluates consumers’ preferences for GM products with a specific medical 
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benefit to clearly identify the products’ potential beneficiaries.  Specifically, we ask Japanese 
consumers suffering from a cedar pollen allergy if they would want to consume GM rice 
(“medical rice” hereafter) which has the same effect as immunotherapy. The study’s focus on a 
GM food with a specific medical benefit and its limiting of survey respondents to the food’s 
beneficiaries should ensure that its observed preference consists of the upper bound of 
consumers’ preference for GM crops.  This information should help determine if appealing to 
potential beneficiaries based on the merits of GM crops encourages the diffusion of GM 
technology.  As medical rice is still in the development stage, we identify patients’ preference 
for it through a stated-preference study in which respondents with a cedar pollen allergy indicate 
their preferred option among the treatments listed, including injection versus medical rice, and 
price.   
The contribution of our study is twofold.  Unlike previous studies, we identify the 
potential beneficiaries of a specific GM product to assess their preference for the good that 
provides a medical benefit, allowing us to precisely estimate consumers’ preference for GM 
crops with direct consumer benefits.  We then examine whether the addition of such a new 
functionality might contribute to a wider diffusion of such a GM variety.  Besides its immediate 
contributions, our work is relevant to the debate over the leadership and future of GM technology 
development.  In contrast to the bio-medical industry, private GM technology development 
(except for industrial uses) has been inhibited by consumer health and environmental concerns.  
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A GM product with a medical benefit represents a potential change in the agricultural and food 
landscape.  However, its realization will depend on consumers’ preferences.1 
The remainder of this paper is organized as follows.  Section 2 discusses the needs for 
medical rice in Japan and a framework for estimating consumers’ preference for it.  Section 3 
outlines the empirical model specification and estimation techniques.  Section 4 presents the 
estimation results and highlights the role of the factors affecting the willingness to pay (WTP) for 
medical rice.  Section 5 concludes with a summary of the results and policy implications. 
2. The Needs for Medical Rice and Consumers’ Preference for It 
According to Baba and Nakae (2008), 30 percent of the Japanese population suffers an allergic 
reaction to cedar pollen and other allergens.  The current treatment is immunotherapy through 
injections or the ingestion of a diluted form of the allergen.2  Conventional immunotherapy—
injecting diluted allergen or sublingual immunotherapy—is the only immunotherapy treatment 
available for patients, which requires them to visit hospitals regularly.   
Takaiwa (2004) developed a new recombinant-gene rice variety—medical rice—useful 
in the treatment of cedar pollen allergies.  Although still in the development stage at the 
National Institute of Agrobiological Sciences, Japan, the newly developed medical rice, in 
                                                   
1 Saito et al. (2009), for instance, examine the historical trend in Japanese wheat breeding and find that government 
research programs have developed varieties containing the characteristics Japanese consumers prefer in wheat. 
 
2 According to Okubo (2015), 70 percent of the patients treated with injections experienced a cure or alleviated 




addition to being a nourishing food, can provide allergen resistance.3  Thus, it provides patients 
a tradeoff between general worries over GM technology on the one hand and the rice’s specific 
health benefits on the other.  After considering the opportunity costs of hospital visits to receive 
immunization injections, some allergy patients may weigh the food’s allergen-immunity benefits 
more heavily than their concerns about GM technology.  Therefore, appealing based on the 
merits of consuming medical GM crops might be effective for patients facing a tradeoff between 
general concerns about GM crops and their nutritional/health benefits.   
In evaluating consumers’ perceptions of GM technology, worries about GM’s 
environmental risks, including the prospects of its crossing with local varieties or facilitating 
herbicide-tolerant weed mutations, must also be addressed.  However, potential solutions are 
beginning to emerge.  One is the recent development of the “plant factory,” in which negative-
pressure ventilation minimizes the chances of pollen or herbicide dispersal, reducing the chances 
of interactions with surrounding ecosystems.  Presumably, consumers will compare the goods 
produced in such a manner with their food and medical amenities and with any remaining 
technological and environmental concerns: they will compare its food value to that of 
conventional rice and its medical value to that of conventional immunization methods.  
As medical rice is not yet being marketed, we carried out a choice experiment to 
                                                   
3  Following the Cartagena Protocol on Biosafety, medical rice is currently planted in an experimental field to 
investigate its environmental impacts.  Pursuant to the Pharmaceutical Affairs Law, it must also pass clinical trials 
as a medicine before it can be sold commercially. 
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examine consumers’ acceptance of it (Louviere et al., 2000).4  Survey respondents were limited 
to those living in Japan and allergic to cedar pollen.  We obtained 1,051 responses, half of them 
from females.  The same number of respondents was selected from each of the five-decade 
categories created for an age range of 20 to 69 years.  In a choice experiment, respondents 
indicated their preferred choice among three, including the “I do not buy” option (see Figure 1).5  
The product attributes were (a) treatment method, (b) fee per month, and (c) rice production site 
if the treatment is medical rice6 (see Table 1 for the levels of each attribute7).  As both injection 
and medical rice treatments always appear in choice sets by construction, only (b) fee and (c) 
rice production site vary across choice sets.  A total of 36 choice sets were generated through 
orthogonal design; these were divided into six groups, each containing six choice sets.  In the 
choice experiment, each respondent was randomly assigned to one of the six groups. 
In addition to the stated-preference experiment, we asked respondents about their 
familiarity with immunotherapy treatment (ܫܯ_ܭ), their familiarity with GM crops/technology 
(ܩܯ_ܭ), and their concerns about the environmental risk of GM crops (ܧܸܰ).  We also asked 
about the severity of their allergic reaction (ܵܧܸܧܴܧ) and the opportunity cost of hospital visits 
                                                   
4 An online survey was carried out through Macromill in March 2015. 
 
5 In the survey, respondents were informed that the “I do not choose” option implied that they would continue their 
current treatment (see Figure 1). 
 
6 Patients may refer to factors such as the frequency of hospital visits and the length of the treatment when they 
choose a treatment method.  However, those factors were not considered as an attribute here because they were 
simultaneously determined with the treatment method.  Instead, we provided this information in the survey script. 
 
7 We did not include sublingual immunotherapy in a (a) treatment method because it was recently developed and 
was not a major treatment yet.  Price levels were set based on the results of a preliminary survey. 
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to receive immunization injections (ܤܷܻܵ), as measured by their schedule flexibility.  
Definitions of the variables are provided in Table 2.8  Using the responses, we tested four 
hypotheses: (a) The busier the respondent is, the higher are the opportunity costs of hospital 
visits; (b) The more unfamiliar with GM technology the respondent is, the stronger are the 
general concerns about GM technology; (c) The more severe the typical allergic reaction is 
and/or the more familiar with immunotherapy treatment the respondent is, the greater is the 
preference for immunotherapy treatment; and (d) The more pro-environmental the attitude is, the 
higher is the WTP for a GM crop cultivated in a plant factory.  Among these, the first two 
constitute our key hypotheses, representing a tradeoff between general worries about GM 
technology and the timesaving benefits of medical rice. 
Table 3 presents the summary statistics of the variables.  Average familiarity with 
immunotherapy treatment is 0.31, with a standard deviation of 0.27, implying that awareness of 
immunotherapy as an effective treatment for cedar pollen allergies varies considerably among 
the patients.  Average familiarity with GM products is 0.184.  The risk communication 
literature suggests that information on the benefits and risks of GM food should have been 
adequately provided to consumers, but our average familiarity results indicate that consumers’ 
understanding of GM crops is still limited.  The average level of concern about the 
environmental risk of GM crops 0.62.  As respondents worry moderately about GM’s 
                                                   
8 The appendix shows how we constructed these variables. 
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environmental risks, GM crop production in a plant factory might effectively mitigate their 
environmental concerns.  
Average severity is 0.83, suggesting that most respondents consider their allergic 
reactions to cedar pollen to be very severe and that their quality of life significantly worsens 
during cedar pollen season.  Finally, the average schedule flexibility level, a proxy for the 
opportunity cost of hospital visits, is 0.50, with a standard deviation of 0.28, suggesting that the 
dataset consists of a variety of respondents, ranging from flexible to inflexible in terms of 
scheduling.  Hence, the timesaving advantages of medical rice may appeal to those facing high 
opportunity costs from hospital visits. 
3. Estimation Model 
Discrete choice analysis is applied to model consumers’ preferences for immunotherapy 
treatment.  Suppose that the utility cedar pollen-allergic patient i gains from choosing 
alternative treatment j is expressed as follows: 
(1) ௜ܷ௝ ൌ ௜ܸ௝ ൅ ߝ௜௝, 
where ௜ܸ௝ is the systematic components of the utility from consuming medical rice (݆ ൌ 1), 
receiving injection (݆ ൌ 2), and the opt-out option (݆ ൌ 3).  We suppose that it takes the 
following form: 
(2) ௜ܸଵ ൌ ߚଵ௜ܣܵܥ்ோ ൅ ߚଶܨܧܧଵ ൅ ሺߚଷ௜ ൅ ߚସ௜ܨܣܥܱܴܶ ଵܻሻܴܫܥܧଵ, 
(3) ௜ܸଶ ൌ ߚଵ௜ܣܵܥ்ோ ൅ ߚଶܨܧܧଶ, and  
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(4) ௜ܸଷ ൌ 0, 
where ܣܵܥ்ோ is an alternative-specific constant, which is unity when respondents choose to 
receive immunotherapy treatment and 0 if they decide to continue their current treatment.  ܨܧܧ௝ 
denotes the treatment fee at 1,000 yen per month.  ܴܫܥܧ௝ is a dummy variable, taking a value 
of 1 if a respondent chooses medical rice as immunotherapy treatment and 0 otherwise.  
ܨܣܥܱܴܶ ௝ܻ is another dummy variable, taking a value of 1 if medical rice is produced at a 
closed factory and 0 if it is produced under open-field conditions.   
Parameters ߚଵ௜, ߚଶ, ߚଷ௜, and ߚସ௜ in equations (2) and (3) respectively measure the 
welfare impacts of receiving immunotherapy treatment, paying the treatment fee, consuming 
medical rice, and consuming medical rice produced in a plant factory.  Note that parameters 
ߚଵ௜, ߚଷ௜, and ߚସ௜ are indexed as i, implying that the extent of the utility gain from 
immunotherapy treatment or medical rice consumption varies across consumers depending on 
their personal characteristics.  They are defined as follows: 
(5) ߚଵ௜ ൌ ߚଵ଴ ൅ ߚଵଵܯܣܮܧ௜ ൅ ߚଵଶܣܩܧ௜ ൅ ߚଵଷܵܧܸܧܴܧ௜ ൅ ߚଵସܫܯ_ܭ௜,  
(6) ߚଷ௜ ൌ ߚଷ଴ ൅ ߚଷଵܯܣܮܧ௜ ൅ ߚଷଶܣܩܧ௜ ൅ ߚଷଷܤܷܵ ௜ܻ ൅ ߚଷସܩܯ_ܫܮ௜, and 
(7) ߚସ௜ ൌ ߚସ଴ ൅ ߚସଵܧܰ ௜ܸ, 
where ܩܯ_ܫܮ௜, defined as 1 െ ܩܯ_ܭ௜, measures the level of unfamiliarity with GM food. 
It is expected that the more severe the typical allergic reaction is, the greater is the 
preference for immunotherapy treatment.  Moreover, as the patient becomes more familiar with 
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immunotherapy treatment, preference for that treatment increases.  Hence, both ߚଵଷ and ߚଵସ 
in equation (5) are expected to have positive signs.  The decision between medical rice and 
injection in equation (6) depends on a tradeoff between general worries about GM technology 
and medical rice’s timesaving benefits.  The busier the respondent, the higher the opportunity 
costs of hospital visits and the more likely the choice of medical rice.  On the other hand, 
unfamiliarity with the technology causes serious concerns about GM technology and reduces the 
likelihood of choosing medical rice.  Thus, ߚଷଷ is expected to be positive, while ߚଷସ is 
expected to be negative.  Finally, the more pro-environmental the patient’s attitude is, the 
stronger the preference for the GM crop to be produced in a plant factory, indicating that ߚସଵ in 
equation (7) should be positive. 
 Suppose ߝ௜௝ follows a type I extreme-value distribution.  The parameters in equations 
(2) to (7) can then be estimated by the conditional logit model.  The underlying assumption (IIA 
assumption) is that the relative probability of choosing any two alternatives is independent of the 
availability of any other alternative.  For example, the IIA assumption implies that the choice 
between injection and current treatment (status quo) is independent of the availability of a 
“medical rice” alternative.  However, when medical rice is not available, an individual suffering 
severely from a cedar pollen allergy prefers the definitive treatment and may choose injection 
with a higher probability than status quo.  Graphically, this is represented by the decision tree in 
Figure 2. The upper level of the tree represents the choice between immunotherapy treatment and 
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status quo, while the lower level consists of two choices: medical rice and injection.  If this 
decision tree holds empirically, conditional logit estimates are no longer consistent.  In Section 
4, we therefore present the estimation results of both the conditional logit model and the nested 
logit model based on the decision tree in Figure 2.  All estimates presented in this study are 
obtained through NLOGIT Version 5. 
4. Estimation Results 
4.1. Utility Function Estimates 
Table 4 presents the utility-function parameter estimates of allergy treatment choice.  The left 
column of Table 4 shows the parameter estimates of the conditional logit model.  The parameter 
on the fee (ߚଶ) is negative and significant, implying that patients incur utility loss from a higher 
treatment fee.  Parameters ߚଵ଴ to ߚଵସ represent how respondents’ personal characteristics 
impact the choice between immunotherapy treatment and status quo.  Both parameters ߚଵଷ and 
ߚଵସ are positive and significant, as expected.  Thus, respondents suffering severely from 
allergic reaction to cedar pollen (ܵܧܸܧܴܧ) seek definitive treatment.  Thus, if they have 
considerable knowledge of immunotherapy treatment (ܫܯ_ܭ), they are more likely to choose that 
treatment. 
 Parameters ߚଷ଴ to ߚଷସ measure the effects of personal characteristics on the choice 
between medical rice and injection.  Key parameters, ߚଷଷ and ߚଷସ, take the expected signs and 
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are significant.  The negative sign of β34 suggests that respondents unfamiliar with GM 
technology (ܩܯ_ܫܮ) have serious concerns about it and lower their utility by consuming medical 
rice.  Most importantly, we confirm a tradeoff relationship between general concerns over GM 
technology and medical rice’s timesaving benefits: the positive sign of ߚଷଷ indicates that busier 
people (ܤܷܻܵ) pay higher opportunity costs for hospital visits and are more likely to choose 
medical rice.  In summary, in line with previous studies, our results support the argument that 
improving consumers’ understanding of GM technology is key to increasing their acceptance of 
GM food.  However, improving their understanding is not so easy in reality.  Approximately 
20 years has passed since the first GM food (FLAVR SAVR tomato) was introduced into the 
market but consumers’ knowledge on GM food is still very limited as we discussed in Section 2.9  
Our results, instead, recommend targeting patients with considerable schedule inflexibility as an 
effective alternative for the successful diffusion of medical rice.   
 Concerning the effects of closed factory production on the choice between medical rice 
and injection, the parameter ߚସଵ on environmental concerns about GM technology (ܧܸܰ) is 
positive but not significant.  Hence, we do not find strong evidence that growing GM crops in a 
closed factory mitigates consumers’ environmental concerns or induces them to purchase those 
crops.  A possible explanation for the insignificance of the parameter is that respondents might 
not have completely understood the benefits of closed factory production from the survey script 
                                                   
9 Public perception of GM food is very low in the United States, too (Hallman et al., 2013).  About half of the 
respondents in their survey in 2013 indicate that they know GM food very little or not at all. 
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(see Figure 1).  Providing a picture along with the sentence might have improved their 
understanding and yielded a significant result. 
The right column of Table 4 shows the estimation results of the nested logit model.  
Both estimations―the conditional logit and the nested logit―give qualitatively and 
quantitatively similar results.  Furthermore, the inclusive value parameter for a nest 
“immunotherapy treatment” is not significantly different from 1 even at 10 percent, suggesting 
that the IIA assumption imposed by the conditional logit model holds empirically.  Hence, the 
discussion below is based on the results of the conditional logit model.  
4.2. WTP Estimates for Medical Rice 
To facilitate the economic interpretation of the estimation results in Section 4.1, we estimate the 
WTP for medical rice and injection.  The WTP, obtained as the ratio of the respective parameter 
to the negative of the price parameter, measures the difference between the maximum amount 
respondents are willing to pay for one alternative and that for the other (e.g., immunotherapy 
treatment vs. current treatment).  Because parameters ߚଵ௜, ߚଷ௜, and ߚସ௜ in equations (2) and 
(3) are indexed as i, the WTPs differ across respondents depending on their personal 
characteristics.  Table 5 shows how much the WTPs change when respondents’ characteristics 
change by one unit and their estimated 95 percent confidence intervals.   
Respondents with an average level of allergic reaction to cedar pollen (ܵܧܸܧܴܧ) are 
willing to pay 1,506 (ൌ 1.826 ൈ 0.825 ൈ 1000) yen more for immunotherapy treatment than for 
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their current treatment (status quo).  The WTP increases by 578 (ൌ 1.840 ൈ 0.314 ൈ 1000) yen 
for respondents with an average level of knowledge of immunotherapy treatment (ܫܯ_ܭ).  
Thus, severity of allergic reaction and abundant knowledge of immunotherapy treatment are the 
keys to inducing consumers to choose either medical rice or injection.  Regarding the WTP for 
medical rice, gender has non-negligible impacts: male respondents are willing to pay 660 (ൌ
0.660 ൈ 1 ൈ 1000) yen more for medical rice than are female respondents.  This result is 
consistent with Kirk and McIntosh (2005), who find that men generally do not favor injections as 
much as women do.  Most importantly, the WTP for medical rice for the average respondents is 
305 (ൌ 0.608 ൈ 0.502 ൈ 1000) yen greater than that for injection because of their schedule 
inflexibility (ܤܷܻܵ).  However, it is 544 (ൌ െ0.668 ൈ 0.815 ൈ 1000) yen lower than that for 
injection due to their unfamiliarity with GM technology (ܩܯ_ܫܮ).   
 Thus, the negative welfare impacts of general worries about GM technology exceed the 
positive welfare impacts of the timesaving advantages of medical rice for average respondents.  
However, each respondent is expected to have very different (both positive and negative) views 
on GM technology because both the levels of unfamiliarity with GM technology and schedule 
inflexibility vary greatly across respondents, as Table 3 shows.  This can be confirmed in the 
fourth column of Table 5, which shows a change in WTPs due to a one standard deviation 
change in personal characteristics: the WTP for medical rice is 168 yen greater for respondents 
whose level of schedule inflexibility is one standard deviation greater than the average, while the 
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WTP is 135 yen lower for respondents whose level of unfamiliarity with GM technology is one 
standard deviation greater than the average.  Thus, preference for medical rice is significantly 
different among respondents depending on their personal characteristics.   
To see this more clearly, we compute for each respondent those two factors’ 
contribution to the WTP for medical rice as െ൫ߚଷଷ෢ ܤܷܵ ௜ܻ ൅ ߚଷସ෢ ܩܯ_ܫܮ௜൯ ߚመଶ⁄ .  Then, we 
present its kernel density estimates in Figure 3.  The figure shows considerable variation among 
respondents due to a tradeoff between general concerns about GM technology and medical rice’s 
timesaving benefits.  For most respondents, it takes a negative value, implying that general 
concerns about GM technology have strongly negative impacts on the preference for medical 
rice.  However, the timesaving benefits of medical rice improve respondents’ willingness to 
purchase it.  Indeed, the benefits’ positive impacts outweigh the negative impacts of general 
concerns about GM technology for some respondents, suggesting that targeting allergy patients 
with inflexible schedules will foster the successful diffusion of medical rice. 
Thus, the observed tradeoff relationship between general worries about GM technology 
and medical rice’s specific health benefits indicates a strong potential demand for GM food with 
medical benefits.  As discussed in the introduction, private investment in GM technology has 
been inhibited by consumer health and environmental concerns.  To increase the public 
acceptance of GM technology, future research on GM technology should be directed to highlight 
not only cost but also the medical features of GM crops.  Besides developing GM varieties with 
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medical benefits, a marketing program should be designed to improve consumers’ understanding 
of these features.  
5. Summary and Conclusions 
Perceptions of the health and environmental risks of GM technology have impeded its diffusion 
in developed countries.  As most GM crops appeal directly only to producers, alleviating 
consumers’ concerns about those crops—for example, through frequent communication among 
breeders, researchers, government agencies, and consumers—has been considered the most 
effective way to enhance the diffusion of the technology.   
However, GM crops that can provide direct consumer as well as producer value have 
been recently developed.  The daily consumption of medical rice, one example of such a crop, 
is expected to cure cedar pollen allergies.  Currently, injecting diluted allergen is the only 
immunotherapy treatment available, and this requires regular hospital visits; the timesaving 
benefits of medical rice may appeal to busy patients.  Consumers thus face a tradeoff between 
general worries about GM technology and the rice’s health benefits.  Explaining the advantages 
of medical rice to potential beneficiaries may enhance the diffusion of GM technology.  This 
study uses a stated-choice experiment on the beneficiaries of the technology to examine whether 
the addition of such a new functionality might widen the diffusion of such a GM variety.   
Our results clearly show a tradeoff relationship: the likelihood of choosing medical rice 
increases when respondents are busy but declines if they are unfamiliar with GM technology.  
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As it is not easy to enhance consumer knowledge of GM crops, targeting busy patients would be 
a more effective way of promoting medical rice.  Targeting patients with severe cedar pollen 
allergies and/or improving their understanding of immunotherapy treatment would indirectly 
boost the chances that they will choose medical rice.  On the other hand, we do not find strong 
evidence that producing GM crops in a closed factory would appeal to consumers with a strong 
environmental awareness. 
The importance of balancing costs and medical features in GM research design will 
likely be part of future crop transgenics.  For example, grains have long shelf lives and do not 
require the costly handling that most vaccines do, and can thus be shipped easily once an 
outbreak occurs.  Efforts are already underway to engineer foods with resistance to infectious 
diseases such as cholera.  Nevertheless, our study suggests that attention should be paid early in 
the research program to the envisioned technology’s market acceptability, in terms of not only its 
cost but also its medical features, and a marketing program must be designed to inform and 
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Table 1: Product Attributes in Choice Experiment 
Product attribute Level 
Treatment (a) Rice (b) Injection 
Rice production site (a) Open field (b) Closed factory 
Treatment fee (yen per month) (a) 500 (b) 1,000 (c) 1,500 (d) 2,000 (e) 2,500 (f) 3,000 
 
 
Table 2: Definition of Variables 
Variable Definition 
ASC Dummy: 1 if respondent chooses immunotherapy treatment 
FEE Fee (1,000 yen/month) of immunotherapy treatment (injection/medical rice) 
RICE Dummy: 1 if respondent chooses medical rice 
FACTORY Dummy: 1 if respondent chooses medical rice produced in a closed factory 
BUSY Schedule flexibility: 0 (not busy) to 1 (busy)  
SEVERE Severity of allergic reaction to cedar pollen: 0 (not severe) to 1 (severe) 
IM_K Level of familiarity with immunotherapy treatment: 0 (unfamiliar) to 1 (familiar)
GM_K Level of familiarity with GM food: 0 (unfamiliar) to 1 (familiar) 
GM_IL Level of unfamiliarity with GM food defined as 1 െ ܩܯ_ܭ 
ENV Environmental concerns about GM technology: 0 (none) to 1 (strong) 
 
 
Table 3: Summary Statistics 
Variable Mean Std. dev. Min Max 
AGE 44.660 13.763 20 69 
BUSY 0.503 0.277 0 1 
SEVERE 0.825 0.174 0 1 
IM_K 0.313 0.268 0 1 
GM_K 0.184 0.202 0 1 





Table 4: Utility Function Estimates of Allergy Treatment Choice 
Variable 
Conditional logit Nested logit 
Coefficient Std. err. Coefficient Std. err 
ASCTR       
 Constant (β10) -0.606 *** 0.187 -0.647 *** 0.209 
 MALE (β11) 0.037 0.069 0.070  0.080 
 AGE (β12) -0.006 *** 0.003 -0.007 *** 0.003 
 SEVERE (β13) 1.136 *** 0.155 1.269 *** 0.205 
 IM_K (β14) 1.144 *** 0.109 1.291 *** 0.170 
FEE      
 Constant (β2) -0.622 *** 0.025 -0.648 *** 0.032 
RICE       
 Constant (β30) 0.649 *** 0.187 0.646 *** 0.193 
 MALE (β31) 0.411 *** 0.071 0.415 *** 0.072 
 AGE (β32) -0.002 0.003 -0.002  0.003 
 BUSY (β33) 0.378 *** 0.101 0.387 *** 0.106 
 GM_IL (β34) -0.416 *** 0.142 -0.409 *** 0.148 
FACTORY     
 Constant (β40) -0.128 0.114 -0.146  0.120 
 ENV (β41) 0.154 0.162 0.184  0.172 
Inclusive value     
 Treatment  0.890  0.080 
 Status quo  1.000   
Log likelihood -6236.995 -6236.117 
Observations 6306 6306 
Note: *** indicates statistical significance at the 1 percent level.  The inclusive value parameter for a nest “status 






Table 5: Willingness-to-pay Estimates 
Variable WTP 95 percent confidence interval 1 std. dev. change in variable
ASCTR    
 Constant (β10) -0.974 (-1.599, -0.375)  
 MALE (β11) 0.059 (-0.162, 0.281)  
 AGE (β12) -0.010 (-0.018, -0.002) -0.139 
 SEVERE (β13) 1.826 (1.326, 2.348) 0.317 
 IM_K (β14) 1.840 (1.481, 2.220) 0.493 
RICE    
 Constant (β30) 1.044 (0.448, 1.648)  
 MALE (β31) 0.660 (0.430, 0.893)  
 AGE (β32) -0.004 (-0.012, 0.005) -0.053 
 BUSY (β33) 0.608 (0.286, 0.936) 0.168 
 GM_IL (β34) -0.668 (-1.123, -0.220) -0.135 
FACTORY    
 Constant (β40) -0.206 (-0.565, 0.161)  
 ENV (β41) 0.248 (-0.271, 0.758) 0.062 














Assume a hospital at which you receive medical treatment is 20 minutes away.  The medical 
fee is fixed no matter which treatment you choose (rice or injection).  However, the treatment 
fee does vary.  In the case of injection treatment, you will have to visit the hospital once a 
week or once a month, while, in the case of medical rice, you will eat one bowl of medical rice 
per day and visit the hospital once a month.  You will have to continue this treatment for 2 to 
3 years, including in the non-spreading season of cedar pollen.  With regard to the rice 
production site, there are two options: an open field means a conventional production site, while 
a closed factory requires negative-pressured ventilation in the plant.   
Based on this information, please choose your most preferred treatment.  If you do 
not prefer any option, please choose [c].  Please note that the “I do not choose” option implies 
that you are continuing your current treatment. 
 
 [a] [b] [c] 
Treatment Medical Rice Injection 
I Do Not choose Fee per month 1,000 500 




Figure 3: WTP for Medical Rice Arising from Schedule Inflexibility and General Concerns 




Appendix: Variable Construction 
Here, we explain how we construct the variables used in the estimation.  First, respondents are 
asked to indicate on a scale from 0 (“least”) to 9 (“most”) the extent to which they are made 
uncomfortable by allergic reactions to cedar pollen if they do not receive their current treatment.  
We also ask respondents to indicate their schedule flexibility on a scale from 0 (“enough spare 
time”) to 4 (“very busy”).  These survey results are presented in Tables A1 and A2, respectively.  
From the results, two variables―severity of respondents’ allergic reaction (ܵܧܸܧܴܧ) and their 
opportunity cost of hospital visits to receive immunization injections (ܤܷܻܵ)―are constructed 
by dividing the rank by 9 and 4, respectively, so that the constructed variable takes a value 
between 0 and 1. 
In the next set of questions, we first provide information regarding immunotherapy 
treatment in Table A3, GM technology in Table A4, and the potential environmental risks of GM 
crop cultivation in Table A5.  Then, we ask respondents to indicate how familiar they are with 
each of them on a Likert scale from 0 (“do not know at all”) to 4 (“know very well”) in Tables 
A3 and A4.  In Table A5, we ask them to indicate the extent to which they are concerned about 
each of the environmental risks on a Likert scale from 0 (“not at all”) to 4 (“very much”).  To 
construct a composite Likert variable ܫܯ_ܭ, we sum the ranks of all the items in Table A3 and 
divide the result by 24.  Variables ܩܯ_ܭ and ܧܸܰ are similarly constructed by summing the 
ranks in Tables A4 and A5 and dividing them by 40 and 20, respectively.  
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Table A1: The Level of Discomfort Due to Allergic Reactions 
To what extent are you made uncomfortable by allergic reactions to cedar pollen? No. % 









9 (Most) 373 35.5
 
 
Table A2: Respondents’ Schedule Flexibility 
To what extent are you flexible with your schedule? No. % 
0 (Enough spare time) 98 9.3 
1 258 24.6 
2 313 29.8 
3 297 28.3 
4 (Very busy) 85 8.1 
 
 
Table A3: The Level of Familiarity with Immunotherapy Treatment 
How familiar are you with the following 
information about immunotherapy treatment? 
Do not know at all    Know very well
0 1 2 3 4 
In immunotherapy treatment, diluted allergen is 
ingested to alleviate allergic reactions 
224 290 248 201 88 
(21.3) (27.6) (23.6) (19.1) (8.4) 
Immunotherapy treatment occasionally causes 
anaphylactic shock 
415 248 184 137 67 
(39.5) (23.6) (17.5) (13.0) (6.4) 
Two to five years are required for a definitive cure 
by immunotherapy treatment 
446 210 180 146 69 
(42.4) (20.0) (17.1) (13.9) (6.6) 
Not all patients are necessarily cured definitively of 
allergic reaction through immunotherapy treatment 
393 247 195 153 63 
(37.4) (23.5) (18.6) (14.6) (6.0) 
Immunotherapy is the only definitive treatment for 
allergic reaction to cedar pollen 
514 209 180 108 40 
(48.9) (19.9) (17.1) (10.3) (3.8) 
Injection or sublingual immunotherapy is the only 
immunotherapy treatment available for patients 
440 252 191 125 43 
(41.9) (24.0) (18.2) (11.9) (4.1) 
Note: Numbers in parentheses represent the share of respondents.  
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Table A4: The Level of Familiarity with GM Food 
How familiar are you with the following 
information about GM food? 
Do not know at all         Know very well
0 1 2 3 4 
GM plants with herbicide tolerance are 
commercially produced in foreign countries 
536 250 148 88 29 
(51.0) (23.8) (14.1) (8.4) (2.8) 
GM crops are used in many processed 
products such as cooking oil in Japan  
475 289 190 79 18 
(45.2) (27.5) (18.1) (7.5) (1.7) 
60% of cooking oil processed in Japan is 
made from GM crops 
647 216 127 49 12 
(61.6) (20.6) (12.1) (4.7) (1.1) 
Japan imports a lot of GM crops for several 
purposes such as animal feeds 
523 269 163 75 21 
(49.8) (25.6) (15.5) (7.1) (2.0) 
90% of soybeans produced in the U.S. and 
Brazil are GM crops 
642 190 133 66 20 
(61.1) (18.1) (12.7) (6.3) (1.9) 
The use of GM crops may not be displayed on 
the labels of cooking oil in Japan  
723 145 116 39 28 
(68.8) (13.8) (11.0) (3.7) (2.7) 
The use of GM soybeans must be displayed 
on the labels of food products in Japan 
472 214 199 114 52 
(44.9) (20.4) (18.9) (10.9) (5.0) 
Cross-breeding has occurred between wild 
and GM species in Japan 
760 136 104 38 13 
(72.3) (12.9) (9.9) (3.6) (1.2) 
Research on GM crops is regulated by law 
602 224 140 70 15 
(57.3) (21.3) (13.3) (6.7) (1.4) 
Except for flowers, GM plants are not 
commercially produced in Japan  
770 136 99 34 12 
(73.3) (12.9) (9.4) (3.2) (1.1) 
Note: Numbers in parentheses represent the share of respondents. 
 
Table A5: The Level of Environmental Concerns about GM Technology 
How much are you concerned about the following 
potential environmental risks of GM crop cultivation?
Not at all               Very much
0 1 2 3 4 
Interactions between GM species and surrounding 
ecosystems may cause serious problem in nature 
81 120 326 373 151 
(7.7) (11.4) (31.0) (35.5) (14.4)
Diffusion of GM crop production due to cross-
breeding between non-GM and GM crops 
84 112 325 374 156 
(8.0) (10.7) (30.9) (35.6) (14.8)
GM crops may produce and spread toxic chemicals 
into nature 
71 78 287 384 231 
(6.8) (7.4) (27.3) (36.5) (22.0)
GM crop cultivation may facilitate herbicide-tolerant 
weed mutations 
74 92 357 368 160 
(7.0) (8.8) (34.0) (35.0) (15.2)
Overuse of insect-resistant GM crops makes insects 
resistant to those crops 
78 66 322 393 192 
(7.4) (6.3) (30.6) (37.4) (18.3)
Note: Numbers in parentheses represent the share of respondents. 
